Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats locally advanced or metastatic non-small cell lung cancer (NSCLC) with a…. Sold as Retevmo. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Selpercatinib (sold as Retevmo), first approved May 8, 2020, with 13 new uses approved and 0 published complete response letters.
First approved: May 8, 2020
Applications: 2
New uses approved: 13
Complete response letters: 0
Medicare spending, 2025: $120M
Orphan exclusivity until: May 29, 2031
First approved in the EU: Feb 11, 2021
First approved in Japan: Sep 27, 2021
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 17 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
RetevmoDrugs with a new indication and a new dosage for the treatment of RET fusion gene-positive advanced or recurrent solid tumor. · Eli Lilly Japan K.K. · Jun 24, 2024
RetevmoDrugs with a new indication and a new dosage for the treatment of RET fusion gene-positive unresectable thyroid cancer and RET gene mutation-positive… · Eli Lilly Japan K.K. · Feb 25, 2022
Retevmo, new ingredientDrugs with a new active ingredient indicated for the treatment of RET fusion gene-positive unresectable advanced or recurrent non-small cell lung cancer. · Eli Lilly Japan K.K. · Sep 27, 2021
Clinical Trials
21 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
